Publications
Spotlight Publication
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Society for Clinical Oncology (ASCO) GI
Jan 23
- Jan 25, 2025
Preliminary Results From a Randomized, Open-Label, Phase 2 Study of Botensilimab With or Without Balstilimab in Refractory Microsatellite Stable Metastatic Colorectal Cancer With No Liver Metastases
Fakih, et al.
Filter by
Phosphopeptide Targets
Nature Communications
Jun 23, 2023
Molecular mechanism of phosphopeptide neoantigen immunogenicity
AGEN2373 (CD137 Agonist)
American Society of Clinical Oncology (ASCO)
Jun 3, 2023
A Phase 1 Study of AGEN2373, a Novel CD137 Agonist Antibody Designed to Avoid Hepatoxicity, in Patients with Advanced Solid Tumors
Barve et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Journal of Clinical Oncology
Apr 11, 2023
Accelerating the Evolution of Immune-Related Enterocolitis Management
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Society of Gynecologic Oncology (SGO)
Mar 27, 2023
Botensilimab, a novel innate/adaptive immune activator, plus balstilimab(anti-PD-1) in patients with recurrent platinum refractory/resistant ovarian cancer
Bockorny B, et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Society of Clinical Oncology (ASCO) GI
Jan 21, 2023
Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in
metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)
El-Khoueiry, et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Connective Tissue Oncology Society (CTOS)
Nov 18, 2022
A Phase IA/IB study of Botensilimab, a novel innate/adaptive immune activator, plus Balstilimab for the treatment of patients with sarcoma
Wilky, et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Society for Immunotherapy of Cancer (SITC)
Nov 11, 2022
Botensilimab, a novel Fc-enhanced anti-CTLA-4 antibody enhances T cell: APC functionality and promotes superior anti-tumor immunity
Levey, et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Society for Immunotherapy of Cancer (SITC)
Nov 12, 2022
Botensilimab, a novel innate/adaptive immune activator with balstilimab (anti-PD-1) in “cold” and I-O refractory metastatic solid tumors
Wilky, et al.
AGEN2373 (CD137 Agonist), INCAGN1876 (GITR Agonist), INCAGN1949 (OX40 Agonist)
Human Antibodies
Jan 1, 2017
Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities
Waight, et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO) GI
Jun 29
- Jul 2, 2022
Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer.
Bullock, et al.
Balstilimab (PD-1 Antagonist), Zalifrelimab (CTLA-4 Antagonist)
Journal of Clinical Oncology
Dec 21, 2021
Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.
O’Malley, et al.
Balstilimab (PD-1 Antagonist), Zalifrelimab (CTLA-4 Antagonist)
Future Oncology
Aug 19, 2021
RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer.
O’Malley, et al.